JO3547B1 - أجسام مضادة ضد تخليق جدار الخلية واستعمالاتها - Google Patents

أجسام مضادة ضد تخليق جدار الخلية واستعمالاتها

Info

Publication number
JO3547B1
JO3547B1 JOP/2013/0036A JOP20130036A JO3547B1 JO 3547 B1 JO3547 B1 JO 3547B1 JO P20130036 A JOP20130036 A JO P20130036A JO 3547 B1 JO3547 B1 JO 3547B1
Authority
JO
Jordan
Prior art keywords
asic1
antibodies
cells expressing
acid
asic1 antibodies
Prior art date
Application number
JOP/2013/0036A
Other languages
English (en)
Inventor
L Lacroix-Fralish Michael
R Morra Marc
Gao Min
M Alessandri Haber Nicole
Macdonald Lynn
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3547(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3547B1 publication Critical patent/JO3547B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بأجسام مضادة وأجزاء منها رابطة لمولد الضد والتي ترتبط تحديداً بالخلايا التي تعبر وراثياً عن قناة أيونية مستشعرة للحمض -1 (<span dir="LTR">ASIC1</span>). ووفقاً لنماذج معينة من الاختراع، تثبط الأجسام المضادة تيارات أيونية ناتجة عن <span dir="LTR">ASIC1</span>، ومستحثة بالحمض في خلايا تعبر وراثياً عن <span dir="LTR">ASIC1</span> البشري. وتكون الأجسام المضادة للاختراع مفيدة لعلاج الألم، بما في ذلك الألم المرتبط بالتدخل الجراحي وأمراض والاضطرابات المتنوعة.
JOP/2013/0036A 2012-01-31 2013-01-30 أجسام مضادة ضد تخليق جدار الخلية واستعمالاتها JO3547B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592837P 2012-01-31 2012-01-31
US201261644038P 2012-05-08 2012-05-08
US201261692925P 2012-08-24 2012-08-24

Publications (1)

Publication Number Publication Date
JO3547B1 true JO3547B1 (ar) 2020-07-05

Family

ID=47666522

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0036A JO3547B1 (ar) 2012-01-31 2013-01-30 أجسام مضادة ضد تخليق جدار الخلية واستعمالاتها

Country Status (33)

Country Link
US (3) US9150648B2 (ar)
EP (2) EP3453723B1 (ar)
JP (1) JP6302844B2 (ar)
KR (1) KR102111941B1 (ar)
CN (1) CN104093738B (ar)
AR (1) AR089852A1 (ar)
AU (1) AU2013215254B2 (ar)
CA (1) CA2862332C (ar)
CL (1) CL2014002019A1 (ar)
CO (1) CO7020877A2 (ar)
CY (2) CY1121368T1 (ar)
DK (2) DK3453723T3 (ar)
EA (1) EA028647B1 (ar)
ES (2) ES2886123T3 (ar)
HK (1) HK1199269A1 (ar)
HR (2) HRP20211541T1 (ar)
HU (2) HUE056335T2 (ar)
IL (2) IL233410A0 (ar)
IN (1) IN2014CN04645A (ar)
JO (1) JO3547B1 (ar)
LT (2) LT3453723T (ar)
MX (1) MX358518B (ar)
MY (1) MY168748A (ar)
NZ (1) NZ626242A (ar)
PH (1) PH12014501613A1 (ar)
PL (2) PL2809681T3 (ar)
PT (2) PT3453723T (ar)
RS (2) RS58439B1 (ar)
SG (1) SG11201403222UA (ar)
SI (2) SI2809681T1 (ar)
TW (1) TWI591073B (ar)
UY (1) UY34603A (ar)
WO (1) WO2013116296A1 (ar)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ626242A (en) 2012-01-31 2017-02-24 Regeneron Pharma Anti-asic1 antibodies and uses thereof
AU2015247742A1 (en) 2014-04-15 2016-11-24 Sorrento Therapeutics, Inc. Antigen binding proteins that bind WISP1
RS60717B1 (sr) 2014-05-16 2020-09-30 Ablynx Nv Varijabilni domeni imunoglobulina
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) * 2016-02-26 2019-08-06 上海科技大学 一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
ES2864529T3 (es) * 2018-01-26 2021-10-14 Regeneron Pharma Anticuerpos y fragmentos de unión a antígeno anti-TMPRSS2
GB2598698B (en) * 2019-06-04 2024-09-18 Univ Shanghai Technology Affinity-maturated anti-ASICIa antibodies
CN114341182B (zh) * 2019-07-11 2024-09-10 纪念斯隆凯特琳癌症中心 Dll3靶向抗体及其用途
CN114867745B (zh) * 2019-07-23 2024-01-12 上海科技大学 Asic1通道拮抗剂抗体
CN114641503A (zh) * 2019-09-13 2022-06-17 纪念斯隆-凯特琳癌症中心 抗cd371抗体及其用途
WO2023019121A2 (en) * 2021-08-09 2023-02-16 Merck Patent Gmbh Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
AU2022337142A1 (en) * 2021-09-02 2024-03-07 Memorial Hospital For Cancer And Allied Diseases Anti-dll3 antibodies and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
AU9732498A (en) 1997-10-29 1999-05-17 Mcgill University Dna encoding a human proton-gated ion channel and uses thereof
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en) 2000-04-25 2003-10-21 University Of Iowa Research Foundation Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en) 2001-05-10 2006-11-07 Centre National De La Recherche Scientifique - Cnrs Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) 2001-07-18 2003-01-18 Philippe Seguela Novel human proton gated ion channel
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20030186860A1 (en) 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
US20070197583A1 (en) 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
SI1527100T1 (sl) * 2002-03-29 2009-12-31 Schering Corp Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
WO2005025518A2 (en) 2003-09-11 2005-03-24 The Uab Research Foundation Inhibition of inward sodium currents in cancer
WO2005074923A1 (en) 2004-02-03 2005-08-18 Agt Biosciences Limited Methods and compositions
WO2006038070A2 (en) 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
US7192500B2 (en) 2004-04-30 2007-03-20 Kimberly-Clark Worldwide, Inc. Process for making a garment including an absorbent assembly
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
EP2284194A1 (en) * 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
MX2007013304A (es) * 2005-04-26 2007-12-13 Pfizer Anticuerpos de p-caderina.
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
JP5382692B2 (ja) * 2006-07-10 2014-01-08 学校法人藤田学園 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
US8618113B2 (en) 2006-07-14 2013-12-31 Medical Research Council Treatment for demyelinating disease
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US7598039B2 (en) 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
EP2137539B1 (en) 2007-04-03 2010-10-06 ILEGUSAVNID, Genetics Resource Centre Minestry of Social Affairs and Health Amiloride sensitive sodium channels associated with panic disorders
WO2008134659A2 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
EP2853897A1 (en) * 2008-05-08 2015-04-01 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en) 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr) 2008-06-06 2012-12-28 Centre Nat Rech Scient Effets analgesiques de la toxine peptidique apetx2
US9403904B2 (en) * 2008-11-07 2016-08-02 Fabrus, Inc. Anti-DLL4 antibodies and uses thereof
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB0922434D0 (en) * 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102234316B (zh) * 2010-05-07 2014-01-29 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途
NZ626242A (en) 2012-01-31 2017-02-24 Regeneron Pharma Anti-asic1 antibodies and uses thereof
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof

Also Published As

Publication number Publication date
PL3453723T3 (pl) 2022-01-03
IL254416A0 (en) 2017-11-30
IL233410A0 (en) 2014-08-31
MX358518B (es) 2018-08-24
CY1124778T1 (el) 2022-11-25
LT3453723T (lt) 2021-09-10
US20130195878A1 (en) 2013-08-01
RS62454B1 (sr) 2021-11-30
JP6302844B2 (ja) 2018-03-28
PT3453723T (pt) 2021-09-07
RS58439B1 (sr) 2019-04-30
US20160002332A1 (en) 2016-01-07
EP2809681A1 (en) 2014-12-10
UY34603A (es) 2013-07-31
AU2013215254A1 (en) 2014-07-03
WO2013116296A1 (en) 2013-08-08
DK3453723T3 (da) 2021-09-13
KR20140125363A (ko) 2014-10-28
EP3453723A3 (en) 2019-04-10
US9150648B2 (en) 2015-10-06
PH12014501613B1 (en) 2014-10-13
CL2014002019A1 (es) 2015-01-16
NZ626242A (en) 2017-02-24
ES2886123T3 (es) 2021-12-16
SI3453723T1 (sl) 2021-11-30
EP3453723A2 (en) 2019-03-13
LT2809681T (lt) 2019-02-11
EA201491452A1 (ru) 2014-11-28
HRP20190358T1 (hr) 2019-04-05
HUE042531T2 (hu) 2019-07-29
EP3453723B1 (en) 2021-08-11
CO7020877A2 (es) 2014-08-11
EA028647B1 (ru) 2017-12-29
PH12014501613A1 (en) 2014-10-13
PL2809681T3 (pl) 2019-05-31
SG11201403222UA (en) 2014-07-30
EP2809681B1 (en) 2018-12-05
CN104093738B (zh) 2018-05-18
MY168748A (en) 2018-11-30
CN104093738A (zh) 2014-10-08
PT2809681T (pt) 2019-02-18
TW201335182A (zh) 2013-09-01
IN2014CN04645A (ar) 2015-09-18
AR089852A1 (es) 2014-09-24
CA2862332C (en) 2021-05-18
IL254416B (en) 2018-03-29
DK2809681T3 (en) 2019-03-11
CA2862332A1 (en) 2013-08-08
US10513557B2 (en) 2019-12-24
HUE056335T2 (hu) 2022-02-28
CY1121368T1 (el) 2020-05-29
JP2015508063A (ja) 2015-03-16
KR102111941B1 (ko) 2020-05-18
US20180222976A1 (en) 2018-08-09
SI2809681T1 (sl) 2019-04-30
AU2013215254B2 (en) 2017-08-31
HK1199269A1 (en) 2015-06-26
BR112014018651A2 (pt) 2017-07-04
ES2707599T3 (es) 2019-04-04
TWI591073B (zh) 2017-07-11
HRP20211541T1 (hr) 2021-12-24
MX2014008541A (es) 2014-10-24

Similar Documents

Publication Publication Date Title
JO3547B1 (ar) أجسام مضادة ضد تخليق جدار الخلية واستعمالاتها
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
NZ707086A (en) Anti-cd40 antibodies and methods of use
WO2015009726A3 (en) Medical uses of cd38 agonists
UA115122C2 (uk) Cd3-зв&#39;язувальна молекула, здатна до зв&#39;язування з cd3 людини і cd3, що не є людським
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
MX341578B (es) Tratamiento de la osteoartritis y del dolor.
EA201791007A3 (ru) Соединения и их применения для модуляции гемоглобина
EA201591426A1 (ru) Соединения и их применения для модуляции гемоглобина
AU2011328009A8 (en) Compounds and methods for treating pain
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
EA201591762A1 (ru) Человеческие антитела к grem1
EA201591432A1 (ru) Соединения и их применения для модуляции гемоглобина
PH12015502829A1 (en) Lectin-like oxidized ldl receptor1 antibodies and methods of use
MX2015017853A (es) Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina de metodos de uso.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
MX2019003619A (es) Formulaciones de bromocriptina.
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
WO2012119045A3 (en) Compositions and uses thereof to ameliorate pain
MX2017001983A (es) Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos.